Binex

One-stop CDMO service for antibodies, bispecific antibodies, Fc-fusion proteins and pDNA, covering cell line development, process development, GMP manufacturing, quality testing and regulatory support; it produces drug substance in animal-cell bioreactors and microbial fermenters and drug product as liquid and lyophilized vials and prefilled syringes.

Biologics GMP manufacturing site in Songdo, Incheon, approved under EMA GMP in November 2024 and U.S. FDA cGMP in January 2025.

Biologics GMP manufacturing site in Osong, Cheongju, North Chungcheong, with 1,000 L and 5,000 L animal-cell culture lines; in October 2026 it passed its first inspection by an overseas regulator, an EMA GMP inspection.

Chemical drug plant in Saha-gu, Busan, mainly producing intestinal regulators and eye drops; the company says it has led the prescription intestinal-regulator market by same-ingredient sales since 2014, and the plant passed an MFDS inspection in 2021.

Reported to have secured about KRW 70 billion in orders in 2025, including production of Celltrion’s Avtozma (tocilizumab biosimilar).

Is expanding the Osong plant; the company says capacity after the expansion will exceed four times that of the Songdo plant.

The Osong plant completed process performance qualification (PPQ) batches for a global pharmaceutical company, passed its first overseas regulatory inspection (EMA GMP) and secured its first commercial manufacturing order; a U.S. FDA inspection is scheduled for early December 2026.